3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neuroblastoma
7
Lymphoma, B-Cell
5
Lymphoma
5
Rhabdoid Tumor
3
Neoplasms
3
Medulloblastoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Ependymoma
2
Enteropathy-Associated T-Cell Lymphoma
2
Brain Neoplasms
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Interventions
Rituximab
53
Cyclophosphamide
50
Lenalidomide
41
fludarabine
24
obinutuzumab
23
Prednisone
19
Bendamustine Hydrochloride
19
Magnetic Resonance Spectroscopy
18
Vincristine
17
Doxorubicin
16
fludarabine phosphate
15
Specimen Handling
15
zanubrutinib
13
Biopsy
12
tazemetostat
10
ibrutinib
10
Whole-Body Irradiation
10
pembrolizumab
9
Peripheral Blood Stem Cell Transplantation
9
venetoclax
8
Mycophenolic Acid
7
Etoposide
7
axicabtagene ciloleucel
6
Radiotherapy
6
CT-P10
6
Therapeutics
5
R-CHOP protocol
5
tafasitamab
4
polatuzumab vedotin
4
acalabrutinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
etoposide phosphate
×
1 year
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled